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A quantitative LC-MS/MS method for simultaneous 
determination of cocaine and its metabolites in whole blood
Xiabin Chen, Xirong Zheng, Kai Ding, Ziyuan Zhou, Chang-Guo Zhan*, and Fang Zheng*
Molecular Modeling and Biopharmaceutical Center and Department of Pharmaceutical Sciences, 
College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY 40536
Abstract
As new metabolic pathways of cocaine were recently identified, a high performance liquid 
chromatography tandem mass spectrometry (LC-MS/MS) method was developed to 
simultaneously determine cocaine and nine cocaine-related metabolites in whole blood samples. 
One-step solid phase extraction was used to extract all of the ten compounds and corresponding 
internal standards from blood samples. All compounds and internal standards extracted were 
separated on an Atlantis T3 (100Å, 3 µm, 2.1 mm × 150 mm I.D) column and detected in positive 
ion and high sensitivity mode with multiple reaction monitoring. This method was validated for its 
sensitivity, linearity, specificity, accuracy, precision, recovery, and stability. All of the ten 
compounds were quantifiable ranging from the lower limit of quantification (LLOQs) of ~10 nM 
(1.9–3.2 ng/ml) to ~1000 nM (190–320 ng/ml) without any interfering substance. Accuracy and 
precision were determined, and both of them were within the acceptance criteria of the United 
States (US) Food and Drug Administration (FDA) and European Medicines Agency (EMA) 
guidelines. The recovery was above 66.7% for all compounds. Stability tests demonstrated the 
stability of compounds under different storage conditions in whole blood samples. The method 
was successfully applied to a pharmacokinetic study with co-administration of cocaine and alcohol 
in rats.
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1. Introduction
Cocaine is one of the most reinforcing and hepatotoxic drugs, accounting for majority of 
illicit drug-related emergency room (ER) visits in the United States [1]. In humans, 
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approximately 40% of cocaine is hydrolyzed to biologically inactive metabolite ecgonine 
methyl ester (EME) by plasma enzyme butyrylcholinesterase (BChE) and liver 
carboxyesterase-2 (CE-2), but more cocaine is biotransformed to benzoylecgonine (BE) via 
hydrolysis catalyzed by CE-1, and to norcocaine via oxidization catalyzed by liver 
microsomal cytochrome P450 (CYP) 3A4 [2, 3]. This metabolic profile of cocaine is highly 
affected by alcohol co-consumption which commonly happens among cocaine users, as 
shown in Figure 1. Especially, alcohol decreases the hydrolysis of cocaine to BE by 
inhibiting the catalytic activity of CE-1 [4, 5]. Meanwhile, ethanol reacts with cocaine via 
catalysis by CE-1 to produce cocaethylene, which is further oxidized to norcocaethylene by 
CYP 3A4 [2, 3]. With alcohol co-administration, ~34% (oral), ~24% (intravenous), or ~18% 
(smoked) of cocaine is converted to cocaethylene through transesterification [6].
Among the cocaine metabolites described above, BE, norcocaine, cocaethylene, and 
norcocaethylene are all physiologically/biologically active. These active metabolites have 
strong physiological effects such as vasoconstrictive effects, causing the hemodynamic 
changes, and producing lethality [7–11]. Recently, the metabolic pathways of those toxic 
compounds were identified during the process of developing therapeutic treatment for 
cocaine abuse. Briefly, BChE can catalyze the hydrolysis of BE to ecgonine (ECG), 
norcocaine to norecgonine methyl ester (NEME), cocaethylene to ecgonine ethyl ester 
(EEE), and norcocaethylene to norecgonine ethyl ester (NEEE) [3, 12–14]
Disastrous medical and social consequences of cocaine make it a high priority to develop an 
anti-cocaine medication for treatment-seeking users [15, 16]. There have been extensive 
efforts in development of therapeutic agents for cocaine abuse [3, 17–27]. Although target-
based, traditional pharmacodynamic approaches using a small-molecule compound to treat 
cocaine abuse have not yielded a truly effective drug [18]. Alternative approaches using 
biologics (vaccines, monoclonal antibodies, and cocaine-metabolizing enzymes) might be 
promising. Preclinical and clinical studies indicate that biologic approaches are effective in 
both blocking cocaine toxicity and reducing drug craving [3, 17, 19–24, 28]. Biologics block 
cocaine’s access to the central nervous system (CNS) or other acting sites by either binding 
with cocaine or hydrolyzing it [21, 25, 26], possibly resulting in a significant change of 
metabolic profile of cocaine. There are extensive ongoing studies in developing highly 
effective medicines and, meanwhile, investigating their effects on the metabolic profiles of 
cocaine in the presence/absence of other substances (e.g. alcohol) co-administered. 
Therefore, it is highly desirable to develop a thoroughly validated bio-analytical method to 
simultaneously determine the blood concentrations of cocaine and related compounds.
A HPLC method with a UV detector was established in our previous studies to characterize 
pharmacokinetic profiles of cocaine and cocaine-related compounds in rats [12, 13, 19]. 
However, the UV method cannot be used to determine EME, ECG, NEME, EEE, and NEEE 
due to the lack of a conjugated system in these compounds. Several GC-MS and LC-MS/MS 
methods have been reported for simultaneous determination of cocaine and its metabolites 
including BE, norcocaine, cocaethylene, EME, and ECG [29–34]. These methods provided 
great separation, sensitivity, and selectivity. However, none of them was developed to 
determine NEME, EEE, or NEEE in whole blood. We hereby present a LC-MS/MS method 
combined with one-step solid phase extraction, allowing simultaneous determination of 
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cocaine and all of the nine cocaine-related compounds. The method was applied to the 
analysis of whole blood samples for pharmacokinetic study in rats with co-administration of 
cocaine and alcohol.
2. Materials and Methods
2.1. Materials
Cocaine, EME, BE, ECG, norcocaine, cocaethylene, EEE, and norcocaethylene were 
provided by the National Institute of Drug Abuse (NIDA) Drug Supply Program (Bethesda, 
MD). NEME and NEEE were synthesized in our own lab for this study with the purity of 
>99%. The isotopic corresponding internal standards (IS) including cocaine-D3, EME-D3, 
BE-D3, ECG-D3, and cocaethylene-D3 were ordered from Cerilliant (Round Rock, TX). 
Ethanol, paraoxon, heparin, HPLC-grade methanol, and acetonitrile were purchased from 
Thermo Fisher Scientific (Waltham, MA). Formic acid was from Sigma-Aldrich (St. Louis, 
MO). Drug-free blank rat whole blood was sampled from male Sprague–Darley rats that 
were ordered from Harlan (Indianapolis, IN). Mixed cation exchange model solid phase 
extraction cartridges (Oasis MCX 1 cc Vac Cartridge, 10 mg) were obtained from Waters 
(Milford, MA).
2.2. Liquid chromatographic and mass spectrometric conditions
A Shimadzu HPLC system (Shimadzu, Kyoto, Japan), consisting of a DGU-20A/3R 
degasser, LC-20AD binary pumps, CBM-20A controller, and SIL-20A/HT auto sampler, 
was used in this study. The chromatographic analysis was carried out using an Atlantis T3 
(100Å, 3 µm, 2.1 mm × 150 mm I.D) column (Waters, Milford, MA) which is a reversed-
phase C18 column. The mobile phase A consisted of 0.1% formic acid and mobile phase B 
consisted of mobile phase A: acetonitrile (10:90, v/v). The flow rate was set at 0.2 ml/min. A 
5 µl injection of each sample was loaded on to the column, separated and eluted using the 
following gradient: 0% B at 0 min, hold 0% B for 5 min, then B increased to 20% at 6 min, 
40% B at 16 min, and 90% B at 18 min, hold 90% B for 4 min, 0% B at 23 min, and re-
equilibrate at 0% B for 5 min. The total run time was 28 min. The column temperature was 
maintained at room temperature (~21°C). The auto sampler temperature was maintained at 
15°C, and the auto sampler injection needle was washed with 200 µl mobile phase A: 
methanol (50:50, v/v) after each sample injection to reduce the carryover.
The mass spectrometer, AB SCIEX tripleTOF™ 5600 (AB SCIEX, Redwood City, CA), 
was run in positive ion and high sensitivity mode under the following conditions and 
settings: positive ions were generated in the source using nitrogen as the source gases. Ion 
source gas 1 (GS1) and 2 (GS2) were set at 25 and 35 respectively, and curtain gas (CUR) 
was set at 40. Source gas temperature was set at 500°C. Ion spray voltage floating (ISVF) 
was 3000 V. Compound-specific ionization parameters, ion transition, declustering potential 
(DP), collision energy (CE), collision energy spread (CES), ion release delay (IRD), and ion 
release width (IRW) were optimized and summarized in Table 1. Analyst® TF 1.7 software 
(AB SCIEX, Redwood City, CA) was used for instrument control and data acquisition. 
MultiQuant™ 3.0 software (AB SCIEX, Redwood City, CA) was used for quantitative 
analysis.
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2.3. Treatment of blood samples for mass spectrometry
The sample extraction method used in this study was established in our previous studies [14, 
35]. Briefly, internal standard (IS) solution (0.1 µM for each IS) with a volume equal to that 
of the whole blood was added to each blood sample. The mixture was vortexed and then 
centrifuged for 15 min at 13,000 rpm; and the supernatant was collected and mixed with 500 
µl 4% formic acid. Before being loaded onto solid-phase extraction column, Oasis MCX 1 
cc Vac Cartridge, conditioned by 1 ml methanol followed by 1 ml water, the sample was 
centrifuged at 13,000 rpm for 15 min. Loaded cartridge was washed twice with 1 ml 
methanol, and the contents were eluted twice with 500 µl methanol/water solution (95:5, v/v, 
with 7.5% ammonium hydroxide). Eluate was evaporated to dryness at 25°C using a vacuum 
concentrator, reconstituted in 74 µl 0.1% formic acid, and centrifuged at 13,000 rpm for 15 
min. Supernatant was transferred to a vial and stored refrigerated until analysis by LC-
MS/MS.
2.4. Preparation of stock, calibration standards and quality control samples
Combined stock solution was prepared by mixing solutions of cocaine and its metabolites 
with those of the corresponding deuterium-labeled IS. The final concentration is 10 µM for 
each analyte, and 0.1 µM for each IS. Combined standard solutions were prepared by 
diluting the combined stock solution using the IS solution (0.1 µM for each IS) to various 
concentrations for each analyte and 0.1 µM for each corresponding IS. Calibration standards 
were prepared by adding 74 µl different concentrations of combined standard solutions into 
174 µl blood mixture (74 µl whole blood + 100 µl paraoxon solution) from untreated 
Sprague-Dawley rats. Quality control samples were prepared in the same manner. The same 
method as described above was used to extract cocaine, nine cocaine-related compounds, 
and all ISs.
2.5. Method validation
Linearity and sensitivity—The validation was performed according to the United States 
(US) Food and Drug Administration (FDA) and European Medicines Agency (EMA) 
guidelines [36, 37]. Calibration curve was established by calculating the ratio of the peak 
area for analyte to that for the internal standard and plotting the ratio as a function of the 
ratio of the analyte concentration to the internal standard. The limit of detection (LOD) was 
considered the lowest concentration of analyte where the signal-noise ratio was greater than 
3. The lower limit of quantification (LLQC) was defined as the lowest concentration of 
analyte with accuracy < 20% of the coefficient of variation (CV) and a precision within 20% 
of the nominal concentration.
Selectivity and carryover—Six sources of blank rat blood were individually analyzed 
and evaluated to determine if any interfering components were more than 20% of the LLQC 
for the analytes and 5% for the internal standards. Carryover was assessed by injection of a 
drug-free blank sample after a high concentration sample. Carryover in the blank sample 
should be less than 20% of the LLQC for the analytes and 5% for the internal standards.
Extraction recovery and matrix effect—Matrix effect and extraction recovery were 
determined in six replicates, at LLOQ, medium, and high concentration for all analytes. 
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Samples were prepared in three ways as described by Liu et al. [2]: (a) prepared in the 
absence of blank matrix, (b) prepared by adding analyte to blank matrix extract, and (c), 
prepared by adding analyte to blank matrix prior to solid phase extraction. The matrix effect 
was calculated by dividing peak area of sample b by sample a; and the extraction recovery 
was calculated by dividing peak area of sample c by sample b.
Precision and accuracy—Accuracy was expressed as the percentage of the determined 
concentration to the nominal concentration of the analyte; and precision was expressed as % 
CV. Intra-day accuracy and precision of this method were assessed by analyzing in a single 
run of six QC samples at three levels including LLOQ, medium QC, and high QC. For inter-
day accuracy and precision, LLOQ, medium QC, and high QC from three runs on three 
different days were evaluated.
Stability—The stability of cocaine and cocaine-related compounds in whole blood was 
evaluated using low, medium, and high QC samples (n = 6 for each level). The analyte was 
considered to be stable if the mean concentration at each level was within ±15% of the 
nominal concentration except for the LLOQ which should be within ±20% of the nominal 
value. The freeze-thaw stability samples were analyzed following four freeze-thaw cycles. 
The short-term stability samples were stored at room temperature for 4 hours, and the long-
term stability samples were stored at −70°C for 4 months.
Animal tests and sample collection—Male Sprague–Darley rats were ordered from 
Harlan (Indianapolis, IN), and housed initially as one or two rats per cage. All rats were 
allowed ad libitum access to food and water and maintained on a 12 h light/12 h dark cycle, 
with the lights on at 8:00 a.m. at a room temperature of 21–22°C. Experiments were 
performed in the same colony room in accordance with the Guide for the Care and Use of 
Laboratory Animals as adopted and promulgated by the National Institutes of Health. The 
animal protocol was approved by the IACUC (Institutional Animal Care and Use 
Committee) at the University of Kentucky. Rats received IP injection of 1 g/kg alcohol 
(n=10) or saline (n=6) followed by cocaine administration (60 mg/kg, IP) 30 min after the 
injection of alcohol. Blood samples (50–75 µl) were collected into a heparin-treated 
capillary tube at 5, 10, 15,20, 30, 45, 60, 90, 120, 180, 240, 300, 360, 420, 480, and 600 min 
after the cocaine administration, and mixed with 100 µl paraoxon solution (250 µM 
paraoxon, 10 U/ml heparin) immediately. Blood samples were stored at −80°C until sample 
extraction.
3. Results and discussion
3.1. Method development
The optimization of sample preparation was performed with rat whole blood. Both 
perchloric acid and formic acid were tested for the sample acidification. With the treatment 
of perchloric acid, majority of protein in blood samples was precipitated, but the extraction 
recovery rates of analytes were significantly lower than those with the treatment of formic 
acid. Thus, the formic acid was chosen to acidify the sample. Various concentrations of 
formic acid with different volumes were also tested to clean up the blood samples before 
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being loaded on the SPE column. Eventually, 4% formic acid with a volume 500 µl was 
selected.
A great challenge for development of this LC-MS/MS method was to separate three pairs of 
compounds: cocaine and norcocaethylene, norcocaine and BE, and ECG and NEME. Both 
compounds within each pair have exactly the same m/z, and very similar physicochemical 
properties and ion transition. Unqualified separation within the pair makes it extremely 
difficult to avoid the interference from each other. To solve this problem, the liquid 
chromatography method was modified according to the well-established method by Dr. 
Imbert [38]. The aqueous phase (phase A) of 2 mM ammonium formate, pH 3.0, was 
replaced by 0.1% formic acid. The gradient program was also adjusted with 0% B for the 
first 5 min separation, and longer holding of the initial condition before the next injection. 
Depicted in Figure 2 are representative chromatograms of cocaine and its metabolites 
detected.
Although the liquid chromatography method was optimized to get the good separation, the 
retention time of ECG (3.27 min) is still close to that of NEME (3.04 min). In order to 
further avoid the interference between ECG and NEME, compound-specific source 
parameters for electrospray ionization were optimized to generate fragment ion of ECG 
mainly at m/z 168.1 and fragment ion of NEME mainly at m/z 136.1.
3.2. Method validation
Selectivity and carryover—Six blank matrix samples from different sources were 
analyzed to access the selectivity. There was no endogenous interference observed. The auto 
sampler injection needle was washed with 200 µl mobile phase A: methanol (50:50, v/v) 
after each sample injection to reduce carryover. Only slight carryover effects (less than 20% 
of the LLQCs for the analytes and 5% for the internal standards) in the blank samples were 
observed. To further avoid the carryover, a 0.1% formic acid sample was always injected 
following the samples.
Linearity and sensitivity—LODs, LLOQs, and regression diagnostics of all analytes 
were reported in Table 2. The LODs and LLOQs for this method ranged from 0.2 to 0.9 
ng/ml and 1.9 to 3.2 ng/ml, respectively, for all the substrates in whole blood samples. The 
calibration curve was linear over the concentration range of LLOQ to ~200/~300 ng/ml, with 
the correlation coefficients (r) > 0.99.
Extraction recovery and matrix effect—Extraction recovery and matrix effect values 
at low, medium, and high concentrations are reported in Table 3. Strongest ion suppression 
was observed for EME at low, medium, and high concentrations, with matrix effects of 
23.2%, 31.2%, and 34.6%, respectively; similarly high matrix effects were also found 
previously for some cocaine metabolites including EME [39] and ECG [34]. On the other 
hand, the matrix effect for EME was similarly strong at all of the EME concentrations such 
that both the sensitivity and the linearity of the calibration curve for EME are satisfactory. 
Interestingly, although similarly strong ion suppression for ECG in the blood matrix was 
reported [34], there was no such strong ion suppression for ECG observed in this study, with 
the matrix effects of ECG 67.6%, 70.2 %, and 71.8% at low, medium, and high 
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concentrations, respectively. The matrix effects of other eight substrates ranged from 52.1% 
to 104.1% at low concentration, from 57.7% to 88.3% at medium concentration, and from 
59% to 84.7% at high concentration. The one-step solid phase extraction yielded good 
recovery rates for all of the 10 analytes, with the extraction recovery rates ranging from 
66.7% to 96.2 at low concentration, from 82.9% to 113.9% at medium concentration, and 
from 76.8% to 96.7 at high concentration.
Precision and accuracy—Intra- and inter-day precision and accuracy were evaluated by 
analyzing QC samples (n = 6) at the low, medium, and high concentrations. The accuracy 
and precision data are summarized in Table 4. The intra-day precision (%CV) was 12.5% or 
less, and the inter-day precision was 13.6% or less. The intra-day accuracy was within 
±13.6, and the inter-day accuracy was within ±15.0. According to the US FDA and EMA 
guidelines [36, 37], the bias values for intra- and inter-accuracy should be within 15% of the 
nominal values for QC samples, except for the LLOQ which should be within 20% of 
nominal concentrations, and the CV values for intra- and inter-precision should not be larger 
than 15% for QC samples, except for the LLOQ which should not exceed 20%. Therefore, 
the accuracy and precision values for the intra- and inter-studies of all of the 10 compounds 
are acceptable.
Stability—The stability testing is very important to evaluate the stability of all substrates 
during the sample collection and handling. The stability of analytes was evaluated at three 
concentrations after long-term and short-term storage, and after four freeze-thaw cycles. 
Results of stability testing are summarized in Table 5. The mean concentration of each 
compound (cocaine or metabolite) at each level was always within 15% of the nominal 
concentration for all stability tests. These results indicate that all compounds were stable at 
room temperature for at least four hours and at −80°C for at least four months; and the QC 
samples of all compounds were not affected by the four freeze-thaw cycles.
3.3. Application of the method
The validated method was used to quantify the concentrations of cocaine and the nine 
related compounds in blood samples collected in a pharmacokinetic study with co-
administration of cocaine and alcohol to rats. The time-dependent blood concentrations of 
cocaine and its metabolites after the IP injection of 60 mg/kg cocaine (30 min after the 
injection of 1 g/kg alcohol or saline) in rats are depicted in Figure 3. For both groups of rats, 
cocaine reached its highest concentration of ~2400 ng/ml 20 min after the injection of 
cocaine, and then slowly fell over the 600-min period. Compared to the group without 
alcohol co-administration, the group with co-administration of alcohol had higher 
concentrations of cocaine and lower concentrations of benzoylecgonine. These data are 
consistent with the notion that alcohol can inhibit CE-1, the principal enzyme catalyzing the 
hydrolysis of cocaine to BE [40]. Meanwhile, CE-1 catalyzes the reaction of alcohol and 
cocaine to produce cocaethylene, which is further oxidized to norcocaethylene by CYP 3A4 
[2, 3]. Overall, part of cocaine was hydrolyzed to biologically inactive product EME, but 
majority of cocaine was converted to physiologically/biologically active metabolites, 
including BE, norcocaine, cocaethylene, and norcocaethylene in the presence of alcohol. 
These active metabolites were further metabolized to compounds (such as ECG and EEE) 
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without or with little physiological effects by the endogenous enzymes, but their 
concentrations fell very slowly.
4. Conclusion
We have successfully developed a simple and rapid LC-MS/MS method combined with one-
step solid phase extraction to simultaneously determine the concentrations of cocaine, EME, 
BE, ECG, norcocaine, NEME, cocaethylene, EEE, norcocaethylene, and NEEE in the rat 
blood samples. Great specificity, sensitivity, linearity, recovery, accuracy, precision, and 
stability of the method have been well demonstrated. With a successful application to a 
pharmacokinetic study in rats with co-administration of cocaine and alcohol, this method 
will be valuable for further studies that aim to characterize anti-cocaine therapeutic agents 
and their effects on metabolic profiles of cocaine in the presence/absence of alcohol.
Supplementary Material
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Highlights
► A LC-MS/MS method to simultaneously detect cocaine and 9 metabolites is 
developed. ► The method is highly sensitive and reliable for all of the 10 compounds 
detected. ► Metabolic profile of cocaine in rats with co-administration of alcohol is 
determined.
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Figure 1. 
Cocaine metabolites produced through hydrolysis, oxidation, and reaction of cocaine with 
alcohol (CH3CH2OH).
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Figure 2. 
Representative chromatograms of cocaine and its metabolites.
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Figure 3. 
Metabolic profiles of cocaine in the presence/absence of alcohol in rats. Rats (n=10 with 
alcohol or n=6 without alcohol) were injected (IP) with 1 g/kg alcohol or saline 30 min 
before the IP injection of 60 mg/kg cocaine.
Chen et al. Page 13
J Pharm Biomed Anal. Author manuscript; available in PMC 2018 February 05.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Chen et al. Page 14
Ta
b
le
 1
O
pt
im
iz
ed
 c
om
po
un
d-
sp
ec
if
ic
 s
ou
rc
e 
pa
ra
m
et
er
s 
fo
r 
el
ec
tr
os
pr
ay
 io
ni
za
tio
n
D
ru
gs
Io
n 
tr
an
si
ti
on
D
P
 (
V
)
C
E
 (
eV
)
C
E
S 
(V
)
IR
D
IR
W
C
oc
ai
ne
30
4.
1→
18
2.
1
10
0
30
3.
0
45
17
E
M
E
20
0.
1→
18
2.
1
80
31
3.
0
45
17
B
E
29
0.
1→
16
8.
1
60
28
3.
0
45
17
E
C
G
18
6.
1→
16
8.
1
40
27
3.
0
45
17
N
or
co
ca
in
e
29
0.
1→
16
8.
1
50
25
3.
0
45
17
N
E
M
E
18
6.
1→
13
6.
1
90
36
3.
0
45
17
C
oc
ae
th
yl
en
e
31
8.
2→
19
6.
1
50
29
3.
0
45
17
E
E
E
21
4.
1→
19
6.
1
40
28
3.
0
45
17
N
or
co
ca
et
hy
le
ne
30
4.
2→
18
2.
1
80
24
3.
0
45
17
N
E
E
E
20
0.
1→
18
2.
1
60
22
3.
0
45
17
C
oc
ai
ne
-D
3
30
7.
2→
18
5.
1
50
30
3.
0
45
17
E
M
E
-D
3
20
3.
1→
18
5.
1
60
30
3.
0
45
17
B
E
-D
3
29
3.
2→
17
1.
1
60
30
3.
0
45
17
E
C
G
-D
3
18
9.
1→
17
1.
1
30
25
3.
0
45
17
C
oc
ae
th
yl
en
e-
D
3
32
1.
2→
19
9.
2
50
28
3.
0
45
17
J Pharm Biomed Anal. Author manuscript; available in PMC 2018 February 05.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Chen et al. Page 15
Ta
b
le
 2
L
in
ea
ri
ty
, r
eg
re
ss
io
n 
di
ag
os
tic
s,
 L
O
D
s,
 a
nd
 L
L
O
Q
s
C
om
po
un
d
L
in
ea
ri
ty
ra
ng
e
(n
g/
m
l)
In
te
rn
al
 s
ta
nd
ar
d
(n
g/
m
l)
Sl
op
e
In
te
rc
ep
t
r
L
O
D
(n
g/
m
l)
L
L
O
Q (n
g/
m
l)
C
oc
ai
ne
3.
0–
30
0
C
oc
ai
ne
-D
3 
(3
0)
0.
72
79
0.
03
19
0.
99
73
0.
9
3.
0
E
M
E
2.
0–
20
0
E
M
E
-D
3 
(2
0)
0.
89
94
0.
03
52
0.
99
84
0.
6
2.
0
B
E
2.
9–
29
0
B
E
-D
3 
(2
9)
0.
69
05
0.
05
62
0.
99
69
0.
9
2.
9
E
C
G
1.
9–
19
0
E
C
G
-D
3 
(1
9)
0.
65
26
0.
02
63
0.
99
65
0.
6
1.
9
N
or
co
ca
in
e
2.
9–
29
0
C
oc
-D
3(
30
)
0.
32
74
0.
00
54
0.
99
74
0.
3
2.
9
N
E
M
E
1.
9–
19
0
C
oc
-D
3(
30
)
0.
08
16
0.
00
44
0.
99
42
0.
2
1.
9
C
oc
ae
th
yl
en
e
3.
2–
32
0
C
oc
ae
th
yl
en
e-
D
3
(3
2)
0.
89
20
0.
01
78
0.
99
86
0.
3
3.
2
E
E
E
2.
1–
21
0
C
oc
-D
3(
30
)
0.
50
01
0.
00
30
0.
99
72
0.
2
2.
1
N
or
co
ca
et
hy
le
ne
3.
0–
30
0
C
oc
-D
3(
30
)
0.
45
90
0.
00
61
0.
99
74
0.
3
3.
0
N
E
E
E
2.
0–
20
0
C
oc
-D
3(
30
)
0.
11
31
0.
00
26
0.
99
66
0.
2
2.
0
J Pharm Biomed Anal. Author manuscript; available in PMC 2018 February 05.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Chen et al. Page 16
Ta
b
le
 3
M
at
ri
x 
ef
fe
ct
 (
M
E
) 
an
d 
ex
tr
ac
tio
n 
re
co
ve
ry
 a
t l
ow
, m
ed
iu
m
, a
nd
 h
ig
h 
co
nc
en
tr
at
io
ns
 in
 r
at
 w
ho
le
 b
lo
od
C
om
po
un
d
L
ow
 c
on
ce
nt
ra
ti
on
M
ed
iu
m
 c
on
ce
nt
ra
ti
on
H
ig
h 
co
nc
en
tr
at
io
n
IS
M
E
 (
%
)
E
R
 (
%
)
M
E
 (
%
)
E
R
 (
%
)
M
E
 (
%
)
E
R
 (
%
)
M
E
 (
%
)
E
R
 (
%
)
C
oc
ai
ne
62
.3
 ±
 8
.3
78
.8
 ±
 1
9.
2
82
.2
 ±
 3
.8
97
.1
 ±
 7
.4
81
.8
 ±
 3
.2
77
.8
 ±
 8
.2
84
.2
 ±
 4
.9
73
.9
 ±
 3
.0
E
M
E
23
.2
 ±
 3
.4
87
 ±
 8
.6
31
.2
 ±
 1
.8
82
.9
 ±
 5
.6
34
.6
 ±
 2
.3
87
.9
 ±
 3
.4
23
.6
 ±
 1
.4
79
.4
 ±
 5
.6
B
E
10
4.
1 
±
 7
.4
96
.2
 ±
 6
.8
82
.8
 ±
 4
.5
11
2.
5 
±
 9
.3
65
.5
 ±
 2
.8
87
.9
 ±
 3
.4
87
.8
 ±
 4
.8
81
.4
 ±
 5
.2
E
C
G
67
.6
 ±
 6
.5
95
.1
 ±
 1
8.
9
70
.2
 ±
 4
.7
11
3.
9 
±
 3
.8
71
.8
 ±
 3
.7
90
.8
 ±
 3
.5
91
.2
 ±
 5
.6
84
.2
 ±
 7
.5
N
or
co
ca
in
e
82
.1
 ±
 6
.1
73
.1
 ±
 3
.1
88
.3
 ±
 4
.8
92
.2
 ±
 8
.3
83
.8
 ±
 4
.4
83
.9
 ±
 8
.9
84
.2
 ±
 4
.9
73
.9
 ±
 3
.0
N
E
M
E
52
.1
 ±
 5
.2
66
.7
 ±
 1
1.
3
57
.7
 ±
 5
.2
98
 ±
 6
.9
59
 ±
 4
.3
91
.5
 ±
 5
.0
84
.2
 ±
 4
.9
73
.9
 ±
 3
.0
C
oc
ae
th
yl
en
e
58
.5
 ±
 4
.8
73
.9
 ±
 4
.9
72
.3
 ±
 2
.6
90
.3
 ±
 2
.9
75
.3
 ±
 4
.1
76
.8
 ±
 6
.3
59
.7
 ±
 4
.8
72
.9
 ±
 4
.3
E
E
E
75
.6
 ±
 7
.7
81
.3
 ±
 1
0.
2
82
.6
 ±
 6
.7
10
3.
7 
±
 8
.2
84
.7
 ±
 4
.2
86
.4
 ±
 4
.5
84
.2
 ±
 4
.9
73
.9
 ±
 3
.0
N
or
co
ca
et
hy
le
ne
79
.9
 ±
 1
0.
6
69
.1
 ±
 4
.7
77
.7
 ±
 5
.7
92
.8
 ±
 2
.8
75
.9
 ±
 4
.3
76
.8
 ±
 8
.4
84
.2
 ±
 4
.9
73
.9
 ±
 3
.0
N
E
E
E
84
.3
 ±
 1
3.
2
86
.5
 ±
 1
1.
5
81
.6
 ±
 1
0.
1
10
0.
3 
±
 1
3.
8
81
.8
 ±
 1
0.
9
96
.7
 ±
 9
.1
84
.2
 ±
 4
.9
73
.9
 ±
 3
.0
L
ow
 c
on
ce
nt
ra
tio
n:
 1
.9
–3
.2
 n
g/
m
l (
0.
01
 µ
M
);
 M
ed
iu
m
 c
on
ce
nt
ra
tio
n:
 9
5–
16
0 
ng
/m
l (
0.
5 
µM
);
 H
ig
h 
co
nc
en
tr
at
io
n:
 1
90
–3
20
 n
g/
m
l (
1 
µM
)
J Pharm Biomed Anal. Author manuscript; available in PMC 2018 February 05.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Chen et al. Page 17
Ta
b
le
 4
T
he
 in
tr
a-
 a
nd
 in
te
r-
da
y 
pr
ec
is
io
n 
an
d 
ac
cu
ra
cy
 o
f 
th
e 
L
C
-M
S/
M
S 
m
et
ho
d 
us
ed
 to
 q
ua
nt
if
y 
co
ca
in
e 
an
d 
its
 r
el
at
ed
 c
om
po
un
d 
in
 w
ho
le
 b
lo
od
 s
am
pl
es
D
ru
g
In
tr
a-
da
y
In
te
r-
da
y
L
M
H
L
M
H
C
V
(%
)
B
ia
s
(%
)
C
V
(%
)
B
ia
s
(%
)
C
V
(%
)
B
ia
s
(%
)
C
V
(%
)
B
ia
s
(%
)
C
V
(%
)
B
ia
s
(%
)
C
V
(%
)
B
ia
s
(%
)
C
oc
ai
ne
10
.3
−
11
.1
7.
1
4.
5
4.
0
0.
3
10
.8
−
13
.3
2.
0
2.
2
0.
6
0.
9
E
M
E
8.
0
−
2.
9
4.
0
−
0.
4
3.
5
−
3.
2
7.
8
−
8.
8
3.
2
3.
3
2.
7
−
0.
2
B
E
11
.1
−
13
.6
5.
9
−
0.
7
7.
1
−
4.
4
0.
7
−
14
.8
1.
1
0.
6
1.
9
−
3.
2
E
C
G
12
.5
9.
7
10
.9
−
3.
7
5.
2
1.
2
6.
9
3.
5
2.
9
−
0.
5
4.
3
1.
7
N
or
co
ca
in
e
2.
5
11
.8
2.
9
2.
3
7.
9
9.
9
0.
9
12
.8
1.
1
3.
4
1.
6
11
.5
N
E
M
E
9.
8
11
.9
4.
2
−
6.
4
5.
9
10
.2
13
.6
8.
5
7.
0
−
11
.1
2.
3
12
.6
C
oc
ae
th
yl
en
e
4.
1
−
11
.6
2.
0
1.
7
5.
8
−
1.
1
1.
9
−
10
.4
0.
5
1.
2
1.
1
−
2.
3
E
E
E
8.
2
5.
7
3.
2
1.
1
3.
4
5.
6
7.
7
−
1.
1
6.
4
−
5.
9
4.
3
10
.1
N
or
co
ca
et
hy
le
ne
2.
2
13
.5
4.
7
3.
3
7.
4
1.
2
1.
2
15
.0
1.
2
1.
8
1.
4
2.
9
N
E
E
E
5.
9
12
.5
3.
5
−
4.
1
6.
0
7.
2
11
.9
11
.4
1.
6
−
5.
8
0.
6
7.
8
L
ow
 c
on
ce
nt
ra
tio
n:
 1
.9
–3
.2
 n
g/
m
l (
0.
01
 µ
M
);
 M
ed
iu
m
 c
on
ce
nt
ra
tio
n:
 9
5–
16
0 
ng
/m
l (
0.
5 
µM
);
 H
ig
h 
co
nc
en
tr
at
io
n:
 1
90
–3
20
 n
g/
m
l (
1 
µM
)
J Pharm Biomed Anal. Author manuscript; available in PMC 2018 February 05.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Chen et al. Page 18
Ta
b
le
 5
St
ab
ili
ty
 o
f 
an
al
yt
es
 in
 w
ho
le
 b
lo
od
 s
am
pl
es
D
ru
g
St
ab
ili
ty
L
ow
 c
on
ce
nt
ra
ti
on
M
ed
iu
m
 c
on
ce
nt
ra
ti
on
H
ig
h 
co
nc
en
tr
at
io
n
C
V
 (
%
)
B
ia
s 
(%
)
C
V
 (
%
)
B
ia
s 
(%
)
C
V
 (
%
)
B
ia
s 
(%
)
C
oc
ai
ne
Fr
ee
ze
-t
ha
w
 (
4 
cy
cl
es
)
15
.0
2.
8
9.
8
−
0.
7
4.
5
−
4.
7
B
en
ch
 to
p 
(4
 h
ou
rs
)
12
.4
2.
3
6.
7
0.
3
4.
8
−
6.
7
L
on
g-
te
rm
 (
−
70
°C
, 4
 m
on
th
s)
17
.7
−
0.
4
9.
9
3.
1
5.
7
−
3.
1
E
M
E
Fr
ee
ze
-t
ha
w
 (
4 
cy
cl
es
)
19
.8
2.
1
9.
8
4.
2
5.
9
4.
0
B
en
ch
 to
p 
(4
 h
ou
rs
)
15
.4
−
9.
6
4.
7
5.
9
6.
9
0.
3
L
on
g-
te
rm
 (
−
70
°C
, 4
 m
on
th
s)
6.
9
−
3.
1
8.
6
6.
3
4.
6
3.
5
B
E
Fr
ee
ze
-t
ha
w
 (
4 
cy
cl
es
)
10
.7
−
0.
9
7.
2
5.
5
7.
9
3.
4
B
en
ch
 to
p 
(4
 h
ou
rs
)
13
.6
−
0.
5
8.
6
0.
7
6.
1
1.
7
L
on
g-
te
rm
 (
−
70
°C
, 4
 m
on
th
s)
9.
3
−
1.
4
5.
1
2.
2
6.
3
3.
8
E
C
G
Fr
ee
ze
-t
ha
w
 (
4 
cy
cl
es
)
14
.9
3.
5
9.
4
10
.2
6.
9
2.
6
B
en
ch
 to
p 
(4
 h
ou
rs
)
9.
5
−
1.
5
4.
8
7.
6
10
.4
3.
6
L
on
g-
te
rm
 (
−
70
°C
, 4
 m
on
th
s)
12
.7
−
4.
9
9.
7
10
.7
6.
5
3.
8
N
or
co
ca
in
e
Fr
ee
ze
-t
ha
w
 (
4 
cy
cl
es
)
8.
2
−
1.
0
11
.7
−
0.
2
3.
2
−
1.
2
B
en
ch
 to
p 
(4
 h
ou
rs
)
8.
4
−
1.
1
4.
6
3.
5
7.
2
0.
6
L
on
g-
te
rm
 (
−
70
°C
, 4
 m
on
th
s)
3.
3
−
2.
9
6.
4
2.
2
4.
2
−
1.
4
N
E
M
E
Fr
ee
ze
-t
ha
w
 (
4 
cy
cl
es
)
12
.4
−
12
.8
6.
6
−
5.
4
9.
4
0.
1
B
en
ch
 to
p 
(4
 h
ou
rs
)
11
.3
−
14
.3
5.
7
−
1.
5
10
.6
−
2.
2
L
on
g-
te
rm
 (
−
70
°C
, 4
 m
on
th
s)
10
.0
−
13
.0
4.
0
−
1.
7
10
.8
−
8.
7
C
oc
ae
th
yl
en
e
Fr
ee
ze
-t
ha
w
 (
4 
cy
cl
es
)
4.
7
0.
7
4.
8
−
3.
7
3.
2
−
4.
1
B
en
ch
 to
p 
(4
 h
ou
rs
)
4.
2
1.
7
4.
5
−
2.
1
7.
6
0.
2
L
on
g-
te
rm
 (
−
70
°C
, 4
 m
on
th
s)
5.
4
3.
7
3.
9
−
1.
8
1.
4
−
0.
6
E
E
E
Fr
ee
ze
-t
ha
w
 (
4 
cy
cl
es
)
7.
0
−
3.
2
9.
4
−
9.
3
7.
7
9.
4
B
en
ch
 to
p 
(4
 h
ou
rs
)
8.
5
1.
2
4.
4
−
4.
4
8.
3
6.
8
L
on
g-
te
rm
 (
−
70
°C
, 4
 m
on
th
s)
6.
2
−
2.
2
8.
8
−
5.
2
13
.5
−
5.
2
N
or
co
ca
et
hy
le
ne
Fr
ee
ze
-t
ha
w
 (
4 
cy
cl
es
)
5.
9
0.
1
7.
2
−
4.
4
5.
4
−
6.
4
B
en
ch
 to
p 
(4
 h
ou
rs
)
3.
2
−
0.
2
7.
2
−
0.
9
4.
1
−
2.
2
J Pharm Biomed Anal. Author manuscript; available in PMC 2018 February 05.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Chen et al. Page 19
D
ru
g
St
ab
ili
ty
L
ow
 c
on
ce
nt
ra
ti
on
M
ed
iu
m
 c
on
ce
nt
ra
ti
on
H
ig
h 
co
nc
en
tr
at
io
n
C
V
 (
%
)
B
ia
s 
(%
)
C
V
 (
%
)
B
ia
s 
(%
)
C
V
 (
%
)
B
ia
s 
(%
)
L
on
g-
te
rm
 (
−
70
°C
, 4
 m
on
th
s)
5.
1
−
1.
0
7.
7
−
1.
3
3.
6
2.
8
N
E
E
E
Fr
ee
ze
-t
ha
w
 (
4 
cy
cl
es
)
4.
9
1.
2
13
.3
3.
3
4.
7
6.
5
B
en
ch
 to
p 
(4
 h
ou
rs
)
8.
6
1.
4
5.
1
2.
4
12
.1
3.
7
L
on
g-
te
rm
 (
−
70
°C
, 4
 m
on
th
s)
10
.1
−
1.
3
8.
1
−
0.
2
9.
0
−
11
.9
L
ow
 c
on
ce
nt
ra
tio
n:
 1
.9
–3
.2
 n
g/
m
l (
0.
01
 µ
M
);
 M
ed
iu
m
 c
on
ce
nt
ra
tio
n:
 9
5–
16
0 
ng
/m
l (
0.
5 
µM
);
 H
ig
h 
co
nc
en
tr
at
io
n:
 1
90
–3
20
 n
g/
m
l (
1 
µM
)
J Pharm Biomed Anal. Author manuscript; available in PMC 2018 February 05.
